Kyung Wan Min
Nowon Eul Ji Medical Center, Eul Ji University in Korea · Eulji University · Department of Internal Medicine, Eulji University Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kyung Wan Min as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:10 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06712615 · Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 DiabetesProGen. Co., Ltd. · active not recruiting · Type 2 Diabetes Mellitus (T2DM), Obesity Type 2 Diabetes Mellitus · principal investigator
- N/ANCT01329822 · Effects of Caloric Restriction on Fetuin-A and Cardiovascular Risk FactorsKorea University · completed · Type 2 Diabetes, Overweight · principal investigator
- N/ANCT00949169 · Carotid Intima-media Thickness (IMT) and Large-vessel Atherosclerosis by Multidetector Computed Tomography (MDCT)Eulji University Hospital · completed · Type 2 Diabetes · principal investigator
- N/ANCT00763074 · Exercise and Diet in Type 2 Diabetic WomenEulji University Hospital · completed · Insulin Sensitivity, Type 2 Diabetes · principal investigator
- N/ANCT00455988 · Developement of Questionnaire to Evaluate a Regularity of Lifestyle in Type 2 Diabetic PatientsEulji University Hospital · unknown · Type 2 Diabetes · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 10 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:10 UTC. The ranking covers the 200 most relevant of 43 PubMed records, and a shared surname and initials can bring in a namesake. All 43 on PubMed
- 236 citationsRCR 7.2
- Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S).J Diabetes Complications · 2014115 citationsRCR 4.0
- Effects of exercise on sRAGE levels and cardiometabolic risk factors in patients with type 2 diabetes: a randomized controlled trial.J Clin Endocrinol Metab · 201288 citationsRCR 3.2
- Resistance exercise did not alter intramuscular adipose tissue but reduced retinol-binding protein-4 concentration in individuals with type 2 diabetes mellitus.J Int Med Res · 201085 citationsRCR 2.7
- Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial.J Diabetes Investig · 201661 citationsRCR 2.5
- Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial.J Diabetes · 201656 citationsRCR 2.2
- The effects of caloric restriction on fetuin-A and cardiovascular risk factors in rats and humans: a randomized controlled trial.Clin Endocrinol (Oxf) · 201349 citationsRCR 1.6
- Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension.Diabetes Obes Metab · 201546 citationsRCR 1.6
- A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.Diabetes Obes Metab · 201345 citationsRCR 1.7
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.Diabetes Obes Metab · 201340 citationsRCR 1.5